Osborne Partners Capital Management LLC Increases Holdings in Pfizer Inc. (NYSE:PFE)

Posted by on Apr 3rd, 2023

Osborne Partners Capital Management LLC boosted its stake in Pfizer Inc. (NYSE:PFE – Get Rating) by 0.4% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 185,616 shares of the biopharmaceutical company’s stock after buying an additional 651 shares during the quarter. Osborne Partners Capital Management LLC’s holdings in Pfizer were worth $9,511,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Harbor Investment Advisory LLC lifted its stake in Pfizer by 3.6% in the 4th quarter. Harbor Investment Advisory LLC now owns 23,977 shares of the biopharmaceutical company’s stock valued at $1,229,000 after buying an additional 825 shares in the last quarter. ZWJ Investment Counsel Inc. lifted its stake in Pfizer by 7.8% in the 4th quarter. ZWJ Investment Counsel Inc. now owns 42,586 shares of the biopharmaceutical company’s stock valued at $2,182,000 after buying an additional 3,075 shares in the last quarter. Matrix Trust Co lifted its stake in Pfizer by 53.5% in the 4th quarter. Matrix Trust Co now owns 12,203 shares of the biopharmaceutical company’s stock valued at $625,000 after buying an additional 4,252 shares in the last quarter. Empirical Finance LLC lifted its stake in Pfizer by 8.4% in the 4th quarter. Empirical Finance LLC now owns 147,554 shares of the biopharmaceutical company’s stock valued at $7,561,000 after buying an additional 11,464 shares in the last quarter. Finally, Louisiana State Employees Retirement System lifted its stake in Pfizer by 1.0% in the 4th quarter. Louisiana State Employees Retirement System now owns 362,700 shares of the biopharmaceutical company’s stock valued at $18,585,000 after buying an additional 3,500 shares in the last quarter. Hedge funds and other institutional investors own 67.62% of the company’s stock.

Pfizer Trading Up 1.0 %

PFE stock opened at $40.80 on Monday. The business has a fifty day simple moving average of $41.98 and a 200-day simple moving average of $45.61. The company has a quick ratio of 1.00, a current ratio of 1.22 and a debt-to-equity ratio of 0.34. Pfizer Inc. has a 52 week low of $39.23 and a 52 week high of $56.32. The company has a market cap of $230.29 billion, a price-to-earnings ratio of 7.45, a PEG ratio of 1.37 and a beta of 0.64.

Pfizer (NYSE:PFE – Get Rating) last announced its quarterly earnings results on Tuesday, January 31st. The biopharmaceutical company reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $1.03 by $0.11. Pfizer had a net margin of 31.27% and a return on equity of 42.03%. The firm had revenue of $24.30 billion during the quarter, compared to analysts’ expectations of $24.40 billion. During the same period in the prior year, the company earned $1.08 EPS. The firm’s revenue was up 1.9% on a year-over-year basis. On average, equities research analysts expect that Pfizer Inc. will post 3.3 EPS for the current year.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and set a $51.00 price target for the company in a report on Tuesday, February 7th. SVB Leerink cut their price target on Pfizer from $49.00 to $48.00 and set a “market perform” rating for the company in a report on Wednesday, February 1st. Berenberg Bank set a $40.00 price target on Pfizer in a report on Tuesday, February 7th. Morgan Stanley cut their price target on Pfizer from $53.00 to $45.00 and set an “equal weight” rating for the company in a report on Wednesday, February 1st. Finally, BMO Capital Markets cut their price target on Pfizer from $55.00 to $53.00 and set an “outperform” rating for the company in a report on Wednesday, February 1st. Nine investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus price target of $50.38.

Insider Buying and Selling

In other Pfizer news, major shareholder Pfizer Inc purchased 1,811,594 shares of the firm’s stock in a transaction that occurred on Friday, March 17th. The stock was purchased at an average cost of $2.76 per share, with a total value of $4,999,999.44. Following the transaction, the insider now owns 5,952,263 shares in the company, valued at $16,428,245.88. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.05% of the stock is owned by corporate insiders.

Pfizer Company Profile

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Read More

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Get Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.